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Clinical Utility of a New Automated Hepatitis C Virus Core 
Antigen Assay for Prediction of Treatment Response in Patients 
with Chronic Hepatitis C
Hepatitis C virus core antigen (HCV Ag) is a recently developed marker of hepatitis C virus 
(HCV) infection. We investigated the clinical utility of the new HCV Ag assay for prediction 
of treatment response in HCV infection. We analyzed serum from 92 patients with HCV 
infection who had been treated with pegylated interferon and ribavirin. HCV Ag levels 
were determined at baseline in all enrolled patients and at week 4 in 15 patients. Baseline 
HCV Ag levels showed good correlations with HCV RNA (r = 0.79, P < 0.001). Mean HCV 
Ag levels at baseline were significantly lower in patients with a sustained virologic response 
(SVR) than in those with a non SVR (relapse plus non responder) based on HCV RNA analysis 
(2.8 log10fmol/L vs. 3.27 log10fmol/L, P = 0.023). Monitoring of the viral kinetics by 
determination of HCV RNA and HCV Ag levels resulted in similarly shaped curves. Patients 
with undetectable HCV Ag levels at week 4 had a 92.3% probability of achieving SVR 
based on HCV RNA assay results. The HCV Ag assay may be used as a supplement for 
predicting treatment response in HCV infection, but not as an alternative to the HCV RNA 
assay.
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INTRODUCTION
Chronic hepatitis C virus (HCV) infection is a major cause of 
liver cirrhosis and hepatocellular carcinoma (1). The primary 
goal of therapy for patients with HCV infection is achievement 
of a sustained virologic response (SVR). Pegylated interferon 
(PEG-IFN) plus ribavirin has become the standard treatment 
for chronic hepatitis C (CHC) (2). In Europe and the US, follow-
ing PEG-IFN plus ribavirin treatment, 40%-50% of patients in-
fected with genotype 1 achieved SVR, and 70%-74% of patients 
infected with genotype 2 or 3 achieved SVR (3,4). SVR rates were 
slightly higher in Korean patients: 53.6%-69.5% and > 80% of 
Korean patients infected with genotype 1 and 2 achieved SVR, 
respectively (5).
 When considering treatment strategies, prediction of the treat-
ment response is important before starting antiviral therapy. 
Currently, the HCV RNA assay is the recommended tool for 
predicting treatment response. Several studies have reported 
that CHC patients with high viral load (> 800,000 IU/mL) have 
lower probabilities of achieving SVR (6-8). Furthermore, it was 
recently postulated that patients with low baseline viral load 
and undetectable HCV RNA by week 4 could be expected to 
have a shorter treatment duration (9,10). However, HCV RNA 
assays are expensive, time-consuming, and require technical 
equipment and highly trained personnel. Therefore, a less ex-
pensive and faster assay for predicting treatment response is 
needed, particularly in low-resource settings.
 Recently, less expensive and time-consuming assays for de-
tecting HCV core antigen (HCV Ag) have become available. The 
HCV core protein is a 21-kDa structural phosphoprotein of the 
HCV capsid and comprising the first 191 amino acids of the vi-
ral polyprotein, which can be detected and quantified in the se-
rum of infected patients by an enzyme immunoassay technique 
(11). HCV Ag levels show good correlation with HCV RNA lev-
els; therefore, this appears to be a useful new test for detecting 
viremia (12-14). In this context, an attractive future approach 
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for monitoring response to antiviral therapy may involve HCV 
viral load monitoring and predicting treatment response by de-
termining HCV Ag levels. However, few studies have investigat-
ed the utility of the HCV Ag assay in this perspective. Therefore, 
the HCV Ag assay cannot be recommended until more data are 
obtained.
 We aimed to evaluate the performance of the HCV Ag assay 
in predicting treatment response to PEG-IFN and ribavirin by 
comparing it with established methods for quantification of 
HCV RNA.
 
MATERIALS AND METHODS
Patients
Ninety-two patients with CHC treated with PEG-IFN plus riba-
virin were enrolled in this study. All patients were over 18 years 
of age and had elevated serum alanine aminotransferase (ALT) 
levels, compensated liver disease, and documented chronic HCV 
infection by serum hepatitis C antibody and HCV RNA testing. 
The Ethics Committee of the hospital approved the study pro-
tocol.
 All patients received a regimen of 180 µg PEG-IFN α-2a (Pega-
sys®, F.Hoffmann-La Roche, Ltd., Basel, Switzerland) or 1.5 µg/
kg PEG-IFN α-2b (Pegintron®, Schering-Plough, Kenilworth, 
NJ, USA) once weekly plus 1,000-1,200 mg ribavirin daily, ac-
cording to body weight. A 48-week treatment was administered 
to patients infected with genotype 1, and a 24-week treatment 
to patients infected with genotype 2. Serum samples were col-
lected from all enrolled patients at baseline and from 15 patients 
at week 4 of therapy and stored at -80°C.
HCV Ag quantification
HCV Ag quantification was performed using ARCHITECT HCV 
Ag (Abbott, Wiesbaden, Germany) with an HCV Ag assay kit 
(Abbott Japan Co., Ltd., Tokyo, Japan). The ARCHITECT HCV 
Ag assay is a two-step quantitative chemiluminescent micropar-
ticle immunoassay run on a fully automated ARCHITECT in-
strument. The sample volume required was approximately 110 
µL, and HCV Ag levels of < 3.0 fmol/L were considered nonre-
active in accordance with the manufacturer’s instructions.
HCV RNA quantification
HCV RNA quantification was determined by the Cobas AmpliP-
rep/Cobas TaqMan HCV assay (CAM/CTM) (Roche Molecular 
Systems, Inc., Pleasanton, CA, USA). The lower detection limit 
of CAM/CTM is 15 IU/mL.
Assessment of efficacy
SVR was defined as an undetectable serum HCV RNA level 24 
weeks after cessation of treatment, and relapse was defined as 
an undetectable HCV RNA level at the end of treatment but HCV 
RNA positive 24 weeks after discontinuation of therapy. No re-
sponse was defined as a detectable HCV RNA level at the end of 
treatment. An early virologic response (EVR) was defined as an 
undetectable HCV RNA level or a decline of at least 2 log from 
baseline at week 12 of treatment. Treatment was stopped at week 
12 in patients with HCV genotype 1 who did not achieve EVR.
Statistical analysis
Descriptive statistics are shown as the mean ± standard devia-
tion or the median range, as appropriate. The correlation be-
tween HCV Ag and HCV RNA levels was calculated using Pear-
son’s correlation coefficient. Differences in the group charac-
teristics were compared by χ2 and Fisher’s exact test for categor-
ical variables and two-sided t-test was used for continuous vari-
ables. To identify independent predictors of SVR, univariate and 
subsequent multivariate regression analyses were used. Hazard 
ratios (HRs) and corresponding 95% CIs were used where indi-
cated.
 A difference was considered statistically significant when the 
P value was < 0.05. Viral quantification results (i.e. HCV RNA 
and HCV Ag) were converted into a logarithmic (log) scale. Sta-
tistical analyses were performed using SPSS software (ver. 18.0; 
SPSS Inc., Chicago, IL, USA).
Ethics statement
The study design was approved by the institutional review board 
at Severance Hospital (IRB No. 4-2013-0851). All subjects sub-
mitted informed consents before enrollment.
 
RESULTS
Baseline characteristics
The baseline characteristics of the 92 patients are described in 
Table 1. At baseline, the log mean HCV RNA level and the mean 
HCV Ag level was 5.96 IU/mL and 2.94 fmol/L, respectively. HCV 
Ag was not detected in 1 patient (1.1%) with genotype 2. The 
HCV RNA level in this patient was 19,900 IU/mL. HCV Ag levels 
showed good correlation with HCV RNA levels in both geno-
types (r = 0.798, P < 0.001 for genotype 1 [Fig. 1A]; r = 0.773, P <  
0.001 for genotype 2 [Fig. 1B]).
 SVR was observed in 64 patients (69.6%), while 19 (20.7%) 
experienced relapse after the end of therapy. Nine (9.7%) pa-
tients with genotype 1 did not show EVR, so they stopped ther-
apy at week 12. Significantly lower baseline HCV RNA levels 
were observed in patients with SVR (mean log10 5.88 IU/mL) 
than is those with non-SVR (mean log10 6.13 IU/mL) (P = 0.045). 
Mean baseline HCV Ag levels were significantly lower in pati-
ents with SVR versus non-SVR (non-SVR: relapse plus non re-
sponder) (2.8 log10 fmol/L for SVR vs. 3.27 log10 fmol/L for non-
SVR, P = 0.023) (Fig. 2).
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Table 1. Baseline characteristics of the study population
Parameters All patients (n = 92) SVR (n = 64, 69.6%) Non-SVR (n = 28, 30.4%) P value*
Age, yr 51.4 ± 1.2 49.6 ± 13.0 55.6 ± 7.7 0.007
Male 41 (44.6) 28 (43.8) 13 (46.4) 0.824
Cirrhosis, clinically diagnosed 11 (12.0) 2 (3.1) 9 (32.1) < 0.001
HCV Genotype (1/2) 56/36 34/30 22/6 0.036
HCV RNA, log10IU/mL 5.96 ± 0.07 5.88 ± 0.79 6.13 ± 0.40 0.045
HCV Ag, log10fmol/L 2.94 ± 0.11 2.80 ± 1.14 3.27 ± 0.76 0.023
Serum albumin, g/dL 4.33 ± 0.04 4.36 ± 0.39 4.24 ± 0.35 0.170
Total bilirubin, mg/dL 0.86 ± 0.04 0.81 ± 0.36 0.98 ± 0.39 0.052
Alanine aminotransferase, IU/L 79.5 ± 6.3 78.4 ± 60.2 82.1 ± 62.9 0.787
Platelet count, 109/L 175.0 ± 6.6 187.0 ± 60.8 147.8 ± 62.3 0.007
Values are expressed as median (range) or No. (%).
SVR, sustained virologic response; HCV, hepatitis C virus; HCV Ag, HCV core antigen.
*SVR vs. Non-SVR.
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Fig. 1. HCV Ag levels show good correlation with HCV RNA levels in both genotypes. r = 0.798, P < 0.001 for genotype 1 (A); r = 0.773, P < 0.001 for genotype 2 (B).
Fig. 2. Baseline HCV levels. (A) RNA levels (log10 IU/mL) in patients with a sustained virologic response (SVR) and non-SVR. The log mean baseline HCV RNA levels are signifi-
cantly lower in patients with SVR (5.88 IU/mL) than non-SVR (6.13 IU/mL) (P = 0.045). (B) Ag levels (log10 fmol/L) in patients with SVR and non-SVR. The log mean baseline 
HCV Ag levels are significantly lower in patients with SVR (2.8 fmol/L) than in those with non-SVR (3.27 fmol/L) in logs (P = 0.023).
Ba
se
lin
e 
HC
V 
RN
A 
lo
g 1
0IU
/m
L
 SVR Non SVR
8
7
6
5
4
3
2
1
0
P = 0.045
5.88 6.13
Ba
se
lin
e 
HC
V 
Ag
 lo
g 1
0fm
ol
/L
 SVR Non SVR
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0
P = 0.023
2.8
3.27
A B
HCV RNA and HCV Ag levels as predictors of SVR
HCV RNA and HCV Ag levels were entered separately into each 
multivariate analysis, along with age and cirrhosis, due to the 
significant correlation between HCV RNA and HCV Ag levels. 
HCV RNA and HCV Ag levels were both independent predic-
tors of SVR (HCV RNA: P = 0.026; adjusted HR 0.968, 95% CI 
0.917-1.023; HCV Ag: P = 0.027, adjusted HR 0.454, 95% CI 0.226-
0.914), together with cirrhosis (Table 2).
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Changes of HCV RNA and HCV Ag levels at week 4 of 
therapy
We investigated early changes of viral load among 15 patients at 
week 4 of therapy. The characteristics of the 15 patients are shown 
in Table 3. After 4 weeks of treatment, 9 patients had undetect-
able HCV RNA and 13 had undetectable HCV Ag. The mean 
HCV RNA level decreased from 6.05 log10IU/mL to 1.81 log10IU/
mL (P < 0.001), and the mean HCV Ag decreased from 3.27 
log10 fmol/L to 0.67 log10fmol/L (P < 0.001). Among the four pa-
tients who had detectable HCV RNA and a loss of HCV Ag at 
week 4, three achieved SVR. As illustrated in Fig. 3, monitoring 
of viral kinetics by determination of either the HCV RNA or the 
HCV Ag concentration resulted in similarly shaped curves.
Predictive value of undetectable HCV RNA and HCV Ag at 
week 4 of treatment on SVR
Table 4 summarizes the positive predictive values (PPVs) and 
negative predictive values (NPVs) of HCV RNA and HCV Ag test-
ing in terms of the response to combination therapy. As shown 
in Table 2, 92.3% of patients with undetectable HCV Ag subse-
quently attained an SVR to therapy, while 50.0% of patients with 
detectable HCV Ag did not attain an SVR to therapy. According 
to HCV RNA testing, the PPV was 100% and the NPV 66.7%.
Table 3. Predictive value of undetectable HCV RNA and HCV Ag at week 4 of the treat-
ment on sustained virologic response
Assay target PPV* NPV†
Undetectable HCV RNA 9/9 (100%) 4/6 (66.7%)
Undetectable HCV Ag 12/13 (92.3%) 1/2 (50.0%)
HCV, hepatitis C virus; HCV Ag, HCV core antigen.
*Positive predictive values (PPVs) correspond to the rate of patients with undetectable 
HCV Ag or HCV RNA levels and subsequent sustained virologic response; †Negative 
predictive values (NPVs) correspond to the rate of patients without undetectable HCV 
Ag or HCV RNA levels and subsequent sustained virologic response.
Fig. 3. Kinetics of HCV RNA and HCV Ag levels during the 4-week treatment period. 
Viral kinetics were monitored by determination of HCV RNA and HCV Ag levels. The 
similarly shaped curves indicate similar kinetics.
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Table 4. Clinical data of 15 patients with available data at 4 weeks after treatment
Patients Age, yr Gender Genotype
HCV RNA at baseline, 
IU/mL
HCV Ag at baseline, 
fmol/L
HCV RNA at 4 weeks, 
IU/mL
HCV Ag at 4 weeks, 
fmol/L
Treatment  
response 
Patient 1 34 F 1 22,400,000 17,139.56 49,000 140.16 SVR
Patient 2 43 M 1 11,700,000 14,444.98 Not detectable Not detectable SVR
Patient 3 56 F 2 14,800,000 13,998.37 Not detectable Not detectable SVR
Patient 4 27 F 1 825,000 1,605.15 718 Not detectable SVR
Patient 5 40 M 1 18,900,000 14,314.95 193 Not detectable SVR
Patient 6 45 M 2 34,500 120.95 Not detectable Not detectable SVR
Patient 7 41 M 2 181,000 269.02 Not detectable Not detectable SVR
Patient 8 69 F 2 3,110,000 321.87 Not detectable Not detectable SVR
Patient 9 19 M 2 372,000 2,950.81 Not detectable Not detectable SVR
Patient 10 47 F 2 2,190,000 3,096.32 Not detectable Not detectable SVR
Patient 11 65 F 2 8,850,000 17,394.41 232 Not detectable Relapse
Patient 12 55 M 2 318,000 812.54 32.5 Not detectable SVR
Patient 13 54 M 2 43,900 134.99 Not detectable Not detectable SVR
Patient 14 64 M 2 86,300 435.4 Not detectable Not detectable SVR
Patient 15 50 F 2 569,000 1,804.14 769 55.83 No response
HCV, hepatitis C virus; HCV Ag, HCV core antigen; SVR, sustained virologic response.
Table 2. Indepdenent predictors of sustained virologic response
Virologic response parameters
Multivariate* Multivariate†
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
 Age, yr 0.976 (0.923-1.032) 0.396 0.968 (0.917-1.023) 0.250 
 Cirrhosis, clinically diagnosed 0.085 (0.013-0.557) 0.010 0.084 (0.012-0.569) 0.011 
 Total bilirubin, mg/dL 0.323 (0.073-1.440) 0.138 0.331 (0.077-1.426) 0.138 
 Platelet count, 109/L 1.000 (1.000-1.000) 0.385 1.000 (1.000-1.000) 0.582 
 HCV RNA, log10IU/mL 0.968 (0.917-1.023) 0.026 
 HCV Ag, log10fmol/L 0.454 (0.226-0.914) 0.027 
CI, confidence interval; HCV, hepatitis C virus; HCV Ag, HCV core antigen.
*HCV RNA adjusted by age, cirrhosis, total bilirubin and platelet count; †HCV Ag adjusted by age, cirrhosis, total bilirubin and platelet count. 
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DISCUSSION
HCV Ag assays were introduced over the last decade (15), and 
in the majority of studies, HCV Ag was detected by enzyme-link-
ed immunosorbent assays or enzyme immunoassays (16-18). 
These quantitative HCV Ag assays became promising alterna-
tives to HCV RNA assays because of their good correlations (12, 
13). However, their low sensitivity prevented their use in clinical 
practice.
 A fully automated chemiluminescent immunoassay with high-
er sensitivity was recently developed to overcome the shortcom-
ings of conventional HCV Ag assays (19). This new HCV Ag as-
say stimulated further studies on the clinical utility of HCV Ag 
testing (20-22). Park et al. (14) showed that HCV Ag assay re-
sults were comparable to those of HCV RNA viral load assay. 
Several studies have demonstrated the utility of antiviral response 
monitoring using the HCV Ag assay (23,24).
 In our study, HCV Ag was detected in 91 of 92 HCV RNA-pos-
itive baseline samples, showing high diagnostic sensitivity, con-
sistent with previous reports (20,25). We also confirmed a sig-
nificant correlation between HCV Ag and HCV RNA levels at 
baseline, irrespective of HCV genotype, again in concordance 
with prior reports (14,22). Following treatment, patients with 
SVR appeared to have lower serum HCV Ag levels prior to treat-
ment (Fig. 2B). Therefore, the association between baseline HCV 
Ag levels and treatment response is similar to that of HCV RNA 
levels, in agreement with previous reports.
 A rapid virologic response (RVR), typically defined as unde-
tectable HCV RNA at week 4 of treatment with PEG-IFN plus 
ribavirin, is increasingly being used to identify patients most 
likely to achieve SVR. Such observations have led to the con-
cept of shortening treatment durations (widely known as re-
sponse-guided therapy). Among patients infected with HCV 
genotype 1 and who achieve RVR, approximately 90% achieve 
SVR after 48 weeks of treatment (26,27). Moreover, shortened 
treatment regimens are appropriate for some patients with RVR 
(28). Thus, the estimation of an early treatment response at week 
4 is of paramount importance. We aimed to elucidate the utility 
of HCV Ag levels at week 4 for predicting treatment response 
and determining treatment duration. Indeed, one finding in 
our study was that an undetectable HCV Ag level at week 4 had 
good reliability as a positive predictor of SVR. Our results indi-
cate that the PPVs of HCV Ag and HCV RNA testing at week 4 
were similar. The difference in the NPVs was based on a limited 
number of cases of non SVR; therefore, this finding should be 
interpreted with caution.
 The introduction of direct-acting antiviral drugs (DAA) for 
CHC patients has radically changed the treatment of chronic 
HCV infections (29-32). The highly elevated SVR and end of 
treatment response rates have challenged the need for regular 
HCV-RNA efficacy monitoring. Furthermore, in consideration 
of the high costs of DAAs, less expensive tests to assess on-treat-
ment responses are needed. Recent studies have demonstrated 
the clinical utility of monitoring HCV Ag in patients with CHC 
taking DAAs (33-35). Aghemo et al. (33) investigated the accu-
racy of the HCV Ag assay in predicting which patients receiving 
DAAs would achieve SVR at week 12 (SVR12). The assays for 
HCV Ag and HCV RNA predicted the patients with SVR12, with 
positive predictive values of 90% and 83%, respectively, at week 
2, and of 89% and 92%, respectively, at week 4. HCV Ag is as use-
ful as HCV RNA in monitoring the treatment efficacy of anti-
HCV DAA regimens, however, validation using larger cohorts is 
warranted.
 Our study had some limitations. First, the number of enrolled 
patients was relatively small. Second, almost all patients who 
could undergo kinetics evaluation achieved SVR. Due to these 
limitations, we were unable to compare baseline HCV Ag levels 
with week 4 HCV Ag levels. Thus, the predictive value of HCV 
Ag at week 4 should be evaluated in further studies.
 A sensitive HCV RNA assay that can detect < 15 IU/mL is the 
gold standard for determining a virologic response in CHC pa-
tients (36). Although the sensitivity of HCV Ag assays has im-
proved, HCV Ag-based treatment response monitoring may 
need to be based on different algorithms than those currently 
in use because HCV RNA assays have a lower detection limit 
than HCV Ag assays. Therefore, the HCV Ag assay is less useful 
in settings that already use the HCV RNA assay. However, quan-
tification of HCV RNA requires careful handling of specimens 
and is more expensive and time-consuming compared with the 
HCV Ag assay, which is based on a simple enzymatic reaction 
(17). Therefore, the HCV Ag assay can be used frequently for 
treatment monitoring, particularly in low-resource settings.
 Our preliminary results show that HCV Ag levels have excel-
lent correlation to HCV RNA levels. Furthermore, we show that 
the kinetics of Ag and viremia are similar. However, the HCV Ag 
assay should be used as a supplement for monitoring antiviral 
therapy, not as an alternative to the HCV RNA assay. Further 
studies monitoring HCV Ag levels at different time points will 
further clarify the clinical utility of this assay.
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